Reviewing Ablynx (OTCMKTS:ABLYF) and Finch Therapeutics Group (NASDAQ:FNCH)

Ablynx (OTCMKTS:ABLYFGet Rating) and Finch Therapeutics Group (NASDAQ:FNCHGet Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Insider and Institutional Ownership

22.7% of Finch Therapeutics Group shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Ablynx and Finch Therapeutics Group, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ablynx 0 0 0 0 N/A
Finch Therapeutics Group 0 0 1 0 3.00

Finch Therapeutics Group has a consensus price target of $17.00, suggesting a potential upside of 737.44%. Given Finch Therapeutics Group’s higher possible upside, analysts plainly believe Finch Therapeutics Group is more favorable than Ablynx.

Risk and Volatility

Ablynx has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.

Valuation & Earnings

This table compares Ablynx and Finch Therapeutics Group’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ablynx $62.73 million 60.74 -$122.67 million N/A N/A
Finch Therapeutics Group $18.53 million 5.21 -$58.16 million ($1.93) -1.05

Finch Therapeutics Group has lower revenue, but higher earnings than Ablynx.

Profitability

This table compares Ablynx and Finch Therapeutics Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ablynx N/A N/A N/A
Finch Therapeutics Group -313.84% -26.15% -23.87%

Summary

Ablynx beats Finch Therapeutics Group on 6 of the 10 factors compared between the two stocks.

Ablynx Company Profile (Get Rating)

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Finch Therapeutics Group Company Profile (Get Rating)

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Receive News & Ratings for Ablynx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ablynx and related companies with MarketBeat.com's FREE daily email newsletter.